Pharma layoffs continue to roil U.K.

In Europe, pharma restructuring has hit the U.K. hardest, industry experts say, with British drugmakers cutting 11 percent to 15 percent of its jobs across the board over the past two years--and the cuts aren't over yet. Report

Suggested Articles

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.